MicroPulse Laser Trabeculoplasty
Safe, Effective and Easy To Perform Treatment
MicroPulse Laser Trabeculoplasty (MLT) provides surgeons an easy to perform, safe and effective treatment option prior to, or in conjunction with, topical medication. MLT affords long-term durability post a single treatment, or with repeat treatments to enhance or to extend IOP-lowering effects. MLT may improve patient compliance by reducing or eliminating their medication burden. Patients tolerate treatment well with minimal to no downtime. The Iridex laser consoles used for MLT, the IQ 532® Laser and IQ 577® Laser, are versatile and ideal for comprehensive practices whose physicians provide medical retina services in addition to glaucoma care.
20-30% IOP reduction for up to 36 months
Less likelihood of an IOP spike than other approaches to laser trabeculoplasty
Can be performed in about 5 to 10 minutes in the office, hospital, or ASC
Well tolerated by patients with no post treatment lifestyle restrictions
Surgical Guide
| Parameters | |
|---|---|
| Wavelength | 532 nm* |
| Contact Lens | Ritch 4-mirror |
| SLA Spot Size | 300 µm |
| Duration | 300 ms |
| Power | 1000 mW |
| Duty Cycle | 15% |
| Treatment | 360° confluent applications; no post-op medication |
* Ahmed I, Gossage D, Vold S. With Years of SLT Data, Why Consider MicroPulse. MicroPulse Education Webinar. June 6, 2013
MicroPulse Laser Trabeculoplasty is both safe and durable. This therapy can be considered a first-line treatment for glaucoma patients, as well as patients who haven’t seen significant effects from medications. Ike Ahmed, MD, FRCSC, University of Toronto, Canada
